Drug
Dupilumab Coformulated With Berahyaluronidase Alfa
Dupilumab Coformulated With Berahyaluronidase Alfa: highest development phase Phase 3, developed by Sanofi. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dupilumab coformulated with berahyaluronidase alfa NCT07919899 | Phase 3 | Dermatitis Atopic |
| Dupilumab coformulated with berahyaluronidase alfa NCT07646548 | Phase 1 |
Latest
No recent events.
Follow Dupilumab Coformulated With Berahyaluronidase Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.